These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 24481412)
1. IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells. Hideshima H; Yoshida Y; Ikeda H; Hide M; Iwasaki A; Anderson KC; Hideshima T Int J Oncol; 2014 Apr; 44(4):1171-6. PubMed ID: 24481412 [TBL] [Abstract][Full Text] [Related]
3. Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL. Juvekar A; Manna S; Ramaswami S; Chang TP; Vu HY; Ghosh CC; Celiker MY; Vancurova I Mol Cancer Res; 2011 Feb; 9(2):183-94. PubMed ID: 21224428 [TBL] [Abstract][Full Text] [Related]
4. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. Shishodia S; Gutierrez AM; Lotan R; Aggarwal BB Cancer Res; 2005 Oct; 65(20):9555-65. PubMed ID: 16230421 [TBL] [Abstract][Full Text] [Related]
5. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells. Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716 [TBL] [Abstract][Full Text] [Related]
6. Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner. Lee KH; Jeong J; Yoo CG J Biol Chem; 2013 Nov; 288(45):32777-32786. PubMed ID: 24085292 [TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. Li C; Chen S; Yue P; Deng X; Lonial S; Khuri FR; Sun SY J Biol Chem; 2010 May; 285(21):16096-104. PubMed ID: 20335171 [TBL] [Abstract][Full Text] [Related]
8. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265 [TBL] [Abstract][Full Text] [Related]
9. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma. Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845 [TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Ma MH; Yang HH; Parker K; Manyak S; Friedman JM; Altamirano C; Wu ZQ; Borad MJ; Frantzen M; Roussos E; Neeser J; Mikail A; Adams J; Sjak-Shie N; Vescio RA; Berenson JR Clin Cancer Res; 2003 Mar; 9(3):1136-44. PubMed ID: 12631619 [TBL] [Abstract][Full Text] [Related]
11. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Berenson JR; Ma HM; Vescio R Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821 [TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway. Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091 [TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells. Singha B; Gatla HR; Manna S; Chang TP; Sanacora S; Poltoratsky V; Vancura A; Vancurova I J Biol Chem; 2014 Jan; 289(5):2687-700. PubMed ID: 24337575 [TBL] [Abstract][Full Text] [Related]
14. Trichothecin induces cell death in NF-κB constitutively activated human cancer cells via inhibition of IKKβ phosphorylation. Su J; Zhao P; Kong L; Li X; Yan J; Zeng Y; Li Y PLoS One; 2013; 8(8):e71333. PubMed ID: 23936501 [TBL] [Abstract][Full Text] [Related]
15. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways. Amschler K; Schön MP; Pletz N; Wallbrecht K; Erpenbeck L; Schön M J Invest Dermatol; 2010 Apr; 130(4):1073-86. PubMed ID: 19940859 [TBL] [Abstract][Full Text] [Related]
17. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772 [TBL] [Abstract][Full Text] [Related]
18. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim. Dai Y; Chen S; Wang L; Pei XY; Kramer LB; Dent P; Grant S Br J Haematol; 2011 Apr; 153(2):222-35. PubMed ID: 21375523 [TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Denlinger CE; Rundall BK; Keller MD; Jones DR Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472 [TBL] [Abstract][Full Text] [Related]
20. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. Allen C; Saigal K; Nottingham L; Arun P; Chen Z; Van Waes C Clin Cancer Res; 2008 Jul; 14(13):4175-85. PubMed ID: 18593997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]